Propel Bio Management
Latest statistics and disclosures from Propel Bio Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PAGP, ACHV, CORT, PHAT, DCTH, and represent 47.86% of Propel Bio Management's stock portfolio.
- Added to shares of these 10 stocks: ARTV (+$5.3M), IMUX, MIST, PALI, AQST, PHAT, Scynexis, KYTX, SLN, IVA.
- Started 4 new stock positions in SGMT, IMUX, Scynexis, SLN.
- Reduced shares in these 10 stocks: VOR (-$5.6M), VRDN, OCS, TRVI, Immunic, CHRS, CMPS, ABEO, KLRS, QURE.
- Sold out of its positions in ALDX, CHRS, EVMN, Immunic, KLRS, NUVB, MSLE, TRVI, VRDN, VOR. CNTB, OCS, QURE.
- Propel Bio Management was a net seller of stock by $-4.3M.
- Propel Bio Management has $191M in assets under management (AUM), dropping by 20.44%.
- Central Index Key (CIK): 0001969764
Tip: Access up to 7 years of quarterly data
Positions held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Propel Bio Management
Propel Bio Management holds 29 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Plains Gp Holdings Lp-cl Comm (PAGP) | 16.2 | $31M | 1.3M | 24.27 |
|
|
| Achieve Life Sciences Comm (ACHV) | 13.8 | $26M | +6% | 4.0M | 6.53 |
|
| Corcept Therapeutics Comm (CORT) | 6.2 | $12M | -7% | 137k | 86.95 |
|
| Phathom Pharmaceuticals I Comm (PHAT) | 6.0 | $11M | +24% | 1.1M | 10.85 |
|
| Delcath Systems Comm (DCTH) | 5.7 | $11M | -11% | 872k | 12.59 |
|
| Milestone Pharmaceuticals Comm (MIST) | 5.2 | $10M | +80% | 7.4M | 1.34 |
|
| Compass Pathways Adrs (CMPS) | 4.2 | $8.1M | -22% | 573k | 14.15 |
|
| Kyverna Therapeutics Comm (KYTX) | 4.1 | $7.9M | +37% | 883k | 8.91 |
|
| Artiva Biotherapeutics In Comm (ARTV) | 3.5 | $6.8M | +375% | 696k | 9.70 |
|
| Abeona Therapeutics Comm (ABEO) | 3.2 | $6.1M | -26% | 983k | 6.18 |
|
| Aquestive Therapeutics In Comm (AQST) | 3.1 | $6.0M | +102% | 1.4M | 4.16 |
|
| Palisade Bio Comm (PALI) | 2.8 | $5.4M | +131% | 2.6M | 2.09 |
|
| Immunic Comm (IMUX) | 2.6 | $5.0M | NEW | 325k | 15.37 |
|
| Inventiva Sa - Comm (IVA) | 2.5 | $4.8M | +76% | 1.3M | 3.78 |
|
| Sab Biotherapeutics Comm (SABS) | 2.2 | $4.2M | +6% | 1.1M | 3.90 |
|
| Orchestra Biomed Holdings Comm (OBIO) | 2.0 | $3.9M | 897k | 4.32 |
|
|
| Celldex Therapeutics Comm (CLDX) | 2.0 | $3.9M | -21% | 104k | 37.21 |
|
| Zevra Therapeutics Comm (ZVRA) | 1.9 | $3.6M | -10% | 254k | 14.34 |
|
| Ocular Therapeutix Comm (OCUL) | 1.8 | $3.5M | -6% | 358k | 9.82 |
|
| 4d Molecular Therapeutics In Comm (FDMT) | 1.8 | $3.4M | -33% | 253k | 13.30 |
|
| Ovid Therapeutics Comm (OVID) | 1.6 | $3.0M | +21% | 1.1M | 2.69 |
|
| Eyepoint Comm (EYPT) | 1.4 | $2.7M | -11% | 192k | 14.30 |
|
| Upstream Bio Comm (UPB) | 1.3 | $2.4M | +2% | 350k | 6.92 |
|
| Scynexis Comm | 1.2 | $2.2M | NEW | 544k | 4.07 |
|
| Silence Therapeutics Adrs (SLN) | 1.1 | $2.1M | NEW | 192k | 10.98 |
|
| Leonabio Comm (LONA) | 0.7 | $1.4M | 149k | 9.19 |
|
|
| Maze Therapeutics Comm (MAZE) | 0.7 | $1.3M | 44k | 29.84 |
|
|
| Corvus Pharmaceuticals Comm (CRVS) | 0.6 | $1.1M | -17% | 70k | 14.94 |
|
| Sagimet Biosciences Inc-a Comm (SGMT) | 0.5 | $973k | NEW | 126k | 7.73 |
|
Past Filings by Propel Bio Management
SEC 13F filings are viewable for Propel Bio Management going back to 2023
- Propel Bio Management 2026 Q2 filed Aug. 13, 2026
- Propel Bio Management 2026 Q1 filed May 14, 2026
- Propel Bio Management 2025 Q4 filed Feb. 11, 2026
- Propel Bio Management 2025 Q3 filed Nov. 12, 2025
- Propel Bio Management 2025 Q2 filed Aug. 13, 2025
- Propel Bio Management 2025 Q1 filed May 15, 2025
- Propel Bio Management 2024 Q4 filed Feb. 14, 2025
- Propel Bio Management 2024 Q3 filed Nov. 13, 2024
- Propel Bio Management 2024 Q2 filed Aug. 12, 2024
- Propel Bio Management 2024 Q1 filed May 13, 2024
- Propel Bio Management 2023 Q4 filed Feb. 14, 2024